2I4Z

Crystal structure of the complex between PPARgamma and the partial agonist LT127 (ureidofibrate derivative). This structure has been obtained from crystals soaked for 6 hours.

Summary for 2I4Z

• Entry DOI: 10.2210/pdb2i4z/pdb
• Related: 1PRG 2I4J 2PRG 4PRG
• Descriptor: Peroxisome proliferator-activated receptor gamma, (2S)-2-(4-{2-[1,3-BENZOXAZOL-2-YL(HEPTYL)AMINO]ETHYL}PHENOXY)-2-METHYLBUTANOIC ACID (3 entities in total)
• Functional Keywords: bundle of alpha-helices and a small four-stranded beta-sheet, transcription
• Biological source: Homo sapiens (human)
• Cellular location: Nucleus: P37231
• Total number of polymer chains: 2
• Total formula weight: 65513.89

Authors

Pochetti, G.,Mazza, F. (deposition date: 2006-08-23, release date: 2007-04-17, Last modification date: 2023-08-30)

Primary citation

Pochetti, G.,Godio, C.,Mitro, N.,Caruso, D.,Galmozzi, A.,Scurati, S.,Loiodice, F.,Fracchiolla, G.,Tortorella, P.,Laghezza, A.,Lavecchia, A.,Novellino, E.,Mazza, F.,Crestani, M.
Insights into the mechanism of partial agonism: crystal structures of the peroxisome proliferator-activated receptor gamma ligand-binding domain in the complex with two enantiomeric ligands
J.Biol.Chem., 282:17314-17324, 2007

PubMed Abstract: The peroxisome proliferator-activated receptors (PPARs) are transcriptional regulators of glucose and lipid metabolism. They are activated by natural ligands, such as fatty acids, and are also targets of synthetic antidiabetic and hypolipidemic drugs. By using cell-based reporter assays, we studied the transactivation activity of two enantiomeric ureidofibrate-like derivatives. In particular, we show that the R-enantiomer, (R)-1, is a full agonist of PPARgamma, whereas the S-enantiomer, (S)-1, is a less potent partial agonist. Most importantly, we report the x-ray crystal structures of the PPARgamma ligand binding domain complexed with the R- and the S-enantiomer, respectively. The analysis of the two crystal structures shows that the different degree of stabilization of the helix 12 induced by the ligand determines its behavior as full or partial agonist. Another crystal structure of the PPARgamma.(S)-1 complex, only differing in the soaking time of the ligand, is also presented. The comparison of the two structures of the complexes with the partial agonist reveals significant differences and is suggestive of the possible coexistence in solution of transcriptionally active and inactive forms of helix 12 in the presence of a partial agonist. Mutation analysis confirms the importance of Leu(465), Leu(469), and Ile(472) in the activation by (R)-1 and underscores the key role of Gln(286) in the PPARgamma activity.

PubMed: 17403688
DOI: 10.1074/jbc.M702316200

Experimental method

X-RAY DIFFRACTION (2.25 Å)